169 related articles for article (PubMed ID: 24556504)
1. Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells.
Siddiqui RA; Harvey KA; Xu Z; Natarajan SK; Davisson VJ
Bioorg Med Chem; 2014 Mar; 22(6):1899-908. PubMed ID: 24556504
[TBL] [Abstract][Full Text] [Related]
2. Characterization of anticancer properties of 2,6-diisopropylphenol-docosahexaenoate and analogues in breast cancer cells.
Harvey KA; Xu Z; Whitley P; Davisson VJ; Siddiqui RA
Bioorg Med Chem; 2010 Mar; 18(5):1866-74. PubMed ID: 20153203
[TBL] [Abstract][Full Text] [Related]
3. Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.
Siddiqui RA; Zerouga M; Wu M; Castillo A; Harvey K; Zaloga GP; Stillwell W
Breast Cancer Res; 2005; 7(5):R645-54. PubMed ID: 16168109
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity.
El-Ashmawy NE; Al-Ashmawy GM; Amr EA; Khedr EG
Life Sci; 2020 Oct; 259():118212. PubMed ID: 32768581
[TBL] [Abstract][Full Text] [Related]
5. A novel 2,6-diisopropylphenyl-docosahexaenoamide conjugate induces apoptosis in T cell acute lymphoblastic leukemia cell lines.
Altenburg JD; Harvey KA; McCray S; Xu Z; Siddiqui RA
Biochem Biophys Res Commun; 2011 Jul; 411(2):427-32. PubMed ID: 21749860
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and in vitro anticancer evaluation of a stearic acid-based ester conjugate.
Khan AA; Alanazi AM; Jabeen M; Chauhan A; Abdelhameed AS
Anticancer Res; 2013 Jun; 33(6):2517-24. PubMed ID: 23749903
[TBL] [Abstract][Full Text] [Related]
7. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
Harvey KA; Xu Z; Saaddatzadeh MR; Wang H; Pollok K; Cohen-Gadol AA; Siddiqui RA
J Neurosurg; 2015 Mar; 122(3):547-56. PubMed ID: 25526274
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV
Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106
[TBL] [Abstract][Full Text] [Related]
9. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone.
Altenburg JD; Bieberich AA; Terry C; Harvey KA; Vanhorn JF; Xu Z; Jo Davisson V; Siddiqui RA
BMC Cancer; 2011 Apr; 11():149. PubMed ID: 21510869
[TBL] [Abstract][Full Text] [Related]
10. Docosahexanoic acid improves chemotherapy efficacy by inducing CD95 translocation to lipid rafts in ER(-) breast cancer cells.
Ewaschuk JB; Newell M; Field CJ
Lipids; 2012 Nov; 47(11):1019-30. PubMed ID: 23054549
[TBL] [Abstract][Full Text] [Related]
11. Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway.
Issat T; Jakóbisiak M; Golab J
Oncol Rep; 2006 Dec; 16(6):1273-6. PubMed ID: 17089049
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells.
Schley PD; Jijon HB; Robinson LE; Field CJ
Breast Cancer Res Treat; 2005 Jul; 92(2):187-95. PubMed ID: 15986129
[TBL] [Abstract][Full Text] [Related]
14. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Moriceau G; Roelofs AJ; Brion R; Redini F; Ebetion FH; Rogers MJ; Heymann D
Cancer; 2012 Feb; 118(3):750-60. PubMed ID: 21751201
[TBL] [Abstract][Full Text] [Related]
17. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines.
Vibet S; Mahéo K; Goré J; Dubois P; Bougnoux P; Chourpa I
Drug Metab Dispos; 2007 May; 35(5):822-8. PubMed ID: 17296624
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
19. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
20. Anticancer phytochemical analogs 37: synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells.
Dandawate P; Ahmad A; Deshpande J; Swamy KV; Khan EM; Khetmalas M; Padhye S; Sarkar F
Bioorg Med Chem Lett; 2014 Jul; 24(13):2900-4. PubMed ID: 24835626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
